Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Imclone systems (IMCL) -- Ignore unavailable to you. Want to Upgrade?

To: IRWIN JAMES FRANKEL who wrote (1860)	1/22/2002 11:12:12 PM
From: The Dodgy Ticker	Read Replies (2) \| Respond to of 2515

Here is a link to a newsletter article that some might find interesting: prohostonline.com

To: IRWIN JAMES FRANKEL who wrote (1860)	1/22/2002 11:41:31 PM
From: Cacaito	Respond to of 2515

Irwin, if Erbitux works fine, but BMY will not look for paying more, they will go for the least from now on, they already mess up big. BMY will most probably work to control board and company. The current management will go to jail, insider trading and witholding information, blatant lies, they will at the least lost control of the company, the whole board has to go. BMY will look for its own interest, not Imcl. Again, the drug application was rejected cause of doubts on efficacy, just try to look for publications on human subjects use and you will find minimal if any, only tons of basic studies publicly available, and anedoctical evidence of some interviews with some clinicians that claim to have seen it work, not enough. Erbitux maybe works, or maybe do not works. It is back to wait for current ongoing trials. Best case for everybody is that indeed is a good drug. But for Imcl management fate is done, their blatant lies are quite obvious. The Wacksals are just high functioning antisocials.